Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Kaltf. Usd

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Feb 11, 2022 3:40pm

288 Views

Post# 34421674

RE:Kaltf. Usd

When the Junior Pharma sector crashed a year ago many folks sold and moved on. Others trimmed their portfolios and held on to their favourites. The odds of a junior pharma stock making it all the way to a successful Phase 3 are staggeringly low. Everyone at some time feels that their choice of miracle product are going to be life changing for the industry and for themselves. It takes about $35 million U$ to take a therapy thru Phase 1 to 3, and that's not counting normal Company operating costs and other day to day admin. The daily volume will show you how much interest is there for your favourite stock. Hopefully things change for you before May.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market